House Dust Mite Allergy (Hdma) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
House Dust Mites (HDM) are a significant component in house dust and are responsible for most allergic reactions to perennial allergens. Allergy to house dust mites is widespread and can trigger allergic reactions such as asthma, eczema, and rhinitis. HDM is arguably the allergenicity king. One of the most common causes of allergy worldwide is atopic reactivity to their products, which affects the eyes, upper and lower airways, skin, and systemic circulation. Dust mites' characteristics have allowed them to colonize the indoor environment in most homes in the world's temperate regions. Dust mites produce a wide range of immunogenic allergens, have proteolytic activity, and are packaged with bacterial DNA, endotoxin, chitin, and other immune-stimulating materials. HDM allergy is the most typical cause of allergic sensitization in asthmatics. HDM extracts derived from mite bodies, excrement, and other emanations are used in HDM allergy's current diagnosis and immunological treatment. To ensure safety, extracts are standardized based on their ability to elicit skin prick test reactions in allergic volunteers rather than allergen content. Understanding the molecular profile of HDM allergens will enable the replacement of extracts with well-defined antigens in known and effective concentrations and the development of new types of immunotherapy based on the allergens, their sequences, and structures.
In the USA, the prevalence of HDMA varies
from ~ 22 MN to 25 MN cases. However, the diagnosis is as low as 40% to 50%
The competitive
landscape of House Dust Mite Allergy (Hdma) includes country-specific approved
and pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of House Dust
Mite Allergy (Hdma) across 8 MM market from the center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
House
Dust Mite Allergy (Hdma) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 HDM SLIT-tablet ALK-Abelló
A/S Phase 3
2 hdmASIT+TM ASIT
Biotech S.A. Phase 2
3 300 IR Stallergenes
Greer Phase 3
4 Tregalizumab T-Balance
Therapeutics GmbH Phase 2
Comments
Post a Comment